[go: up one dir, main page]

DOP2001000229A - Forma de dosificación de fármaco activada por hidrogel - Google Patents

Forma de dosificación de fármaco activada por hidrogel

Info

Publication number
DOP2001000229A
DOP2001000229A DO2001000229A DO2001000229A DOP2001000229A DO P2001000229 A DOP2001000229 A DO P2001000229A DO 2001000229 A DO2001000229 A DO 2001000229A DO 2001000229 A DO2001000229 A DO 2001000229A DO P2001000229 A DOP2001000229 A DO P2001000229A
Authority
DO
Dominican Republic
Prior art keywords
dosage form
core
hydrogel
drug dosage
activated drug
Prior art date
Application number
DO2001000229A
Other languages
English (en)
Inventor
Scott Max Herbig
William John Curatolo
Leah Elizabeth Appel
Walter C Badcock
Ronald Arthur Beyerinck
Mark Brian Chidlaw
Avinash Goving Thombre
Dwayne Thomas Friesen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of DOP2001000229A publication Critical patent/DOP2001000229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificación de liberación controlada comprende núcleo recubierto, comprendiendo el núcleo una composición que contiene fármaco y una composición hinchables de agua y ocupando cada una regiones separadas dentro del núcleo. El recubrimiento que rodea el núcleo es permeable al agua, insoluble en agua y tiene al menos una abertura de suministro. Se describen una diversidad de configuraciones geométricas
DO2001000229A 2000-08-09 2001-08-08 Forma de dosificación de fármaco activada por hidrogel DOP2001000229A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09

Publications (1)

Publication Number Publication Date
DOP2001000229A true DOP2001000229A (es) 2002-09-30

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2001000229A DOP2001000229A (es) 2000-08-09 2001-08-08 Forma de dosificación de fármaco activada por hidrogel

Country Status (30)

Country Link
US (2) US20030086972A1 (es)
EP (1) EP1326587A2 (es)
JP (1) JP2004505907A (es)
KR (1) KR20030024844A (es)
CN (1) CN1461212A (es)
AP (1) AP2001002237A0 (es)
AU (1) AU2002229141A1 (es)
BG (1) BG107538A (es)
BR (1) BR0113067A (es)
CA (1) CA2418907A1 (es)
DO (1) DOP2001000229A (es)
EA (1) EA200300081A1 (es)
EC (1) ECSP034455A (es)
EE (1) EE200300055A (es)
GT (1) GT200100161A (es)
HR (1) HRP20030082A2 (es)
HU (1) HUP0300722A2 (es)
IL (1) IL154012A0 (es)
IS (1) IS6686A (es)
MA (1) MA26939A1 (es)
MX (1) MXPA03001209A (es)
NO (1) NO20030627L (es)
OA (1) OA12365A (es)
PA (1) PA8524901A1 (es)
PE (1) PE20020307A1 (es)
PL (1) PL360658A1 (es)
SV (1) SV2002000586A (es)
TN (1) TNSN01123A1 (es)
UY (1) UY26876A1 (es)
WO (1) WO2002011702A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
NZ518281A (en) * 1999-12-23 2005-01-28 Pfizer Prod Inc Controlled release drug dosage core comprising a drug-containing composition and a water-swellable composition
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
US20040213848A1 (en) 2001-09-28 2004-10-28 Shun-Por Li Modified release dosage forms
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20100137023A (ko) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CA2499955A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Delayed release dosage forms
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
FR2850576B1 (fr) 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
EP1653926A1 (en) * 2003-08-04 2006-05-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
WO2006082500A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
CN101146521A (zh) * 2005-03-14 2008-03-19 太阳医药高级研究有限公司 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
CA2600736A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
WO2007124372A2 (en) * 2006-04-20 2007-11-01 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic methotrexate delivery
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
JP2011512349A (ja) * 2008-02-15 2011-04-21 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッド 経口放出制御錠剤
BR112012010895A2 (pt) * 2009-11-09 2019-09-24 Capsugel Belgium Nv "fornecimento de veículo".
EP2548556B1 (en) 2010-03-19 2016-08-10 Daiichi Sankyo Company, Limited Method for improving dissolvability of anticoagulant
CN103732227B (zh) * 2011-08-10 2017-04-12 第一三共株式会社 含有二胺衍生物的药物组合物
EP2950822B1 (en) * 2013-01-30 2019-04-24 Daewoong Co., Ltd. Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
US10350822B1 (en) * 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
AU2019231699B2 (en) * 2018-03-07 2023-03-09 Andrew Xian Chen Aqueous formulations for insoluble drugs
AU2022280939A1 (en) * 2021-05-28 2023-10-05 Amgen Inc. Formulations of apremilast
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
TW202325285A (zh) * 2021-10-14 2023-07-01 靜岡縣公立大學法人 粉末製劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
SK181099A3 (en) * 1997-07-01 2000-07-11 Pfizer Prod Inc Solubilized sertraline compositions
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
PL348119A1 (en) * 1998-10-13 2002-05-06 Pfizer Prod Inc Sertraline oral concentrate
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
CA2508722A1 (en) * 2002-12-11 2004-06-24 Pfizer Products Inc. Controlled-release of an active substance into a high fat environment

Also Published As

Publication number Publication date
EA200300081A1 (ru) 2003-08-28
SV2002000586A (es) 2002-10-24
JP2004505907A (ja) 2004-02-26
MXPA03001209A (es) 2003-06-30
PL360658A1 (en) 2004-09-20
EP1326587A2 (en) 2003-07-16
WO2002011702A2 (en) 2002-02-14
IL154012A0 (en) 2003-07-31
IS6686A (is) 2003-01-16
NO20030627D0 (no) 2003-02-07
KR20030024844A (ko) 2003-03-26
WO2002011702A3 (en) 2002-11-28
HRP20030082A2 (en) 2003-04-30
US20030086972A1 (en) 2003-05-08
PE20020307A1 (es) 2002-04-23
GT200100161A (es) 2002-03-22
NO20030627L (no) 2003-04-08
AU2002229141A1 (en) 2002-02-18
MA26939A1 (fr) 2004-12-20
US20040052845A1 (en) 2004-03-18
ECSP034455A (es) 2003-03-10
CA2418907A1 (en) 2002-02-14
EE200300055A (et) 2004-12-15
BG107538A (bg) 2003-11-28
PA8524901A1 (es) 2002-04-25
HUP0300722A2 (hu) 2003-11-28
UY26876A1 (es) 2002-03-22
OA12365A (en) 2006-05-16
TNSN01123A1 (fr) 2005-11-10
BR0113067A (pt) 2003-07-01
AP2001002237A0 (en) 2001-09-30
CN1461212A (zh) 2003-12-10

Similar Documents

Publication Publication Date Title
DOP2001000229A (es) Forma de dosificación de fármaco activada por hidrogel
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
DE69925639D1 (de) Glicazidhaltige matrixtablette mit verzögerter wirkstoffverabreichung zur oralen anwendung
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
PA8508901A1 (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
UY25544A1 (es) Forma de dosificación de nefazodona
DE60108255D1 (de) Clarithromycin enthaltende zubereitung mit verlängerter freisetzung
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
DK1345595T3 (da) Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
NO20011217D0 (no) Doseringsform omfattende væskeformulering
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
CL2007003010A1 (es) Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03).
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
ATE445393T1 (de) Tablette mit gefärbtem kern
UY26503A1 (es) " forma de dosificación de fármacos accionada por un hidrogel"
ECSP003856A (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
CO5550461A2 (es) Tratamiento de enfermedad parasitaria
AR030964A1 (es) Una formulacion farmaceutica con una matriz que forma un gel hidrofilico, formulacion que comprende una o mas sustancias activas, y metodo para preparar tal formulacion que tiene una liberacion prolongada sustancialmente independiente de la fuerza ionica